A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Dec 11, 2017

Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in Combination with Intensive Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

TOKYO – December 11, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the first reported data of the investigational agent...

Read more about Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in Combination with Intensive Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia
Dec 6, 2017

Astellas, the Institute of Medical Science of the University of Tokyo, Chiba University, and Asahi Kogyosha Enter into Collaborative Research Agreement on Rice-based Oral Vaccine “MucoRice”

Tokyo, December 6, 2017 - Astellas Pharma Inc. (Tokyo, President and CEO: Yoshihiko Hatanaka, “Astellas” ), the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori...

Read more about Astellas, the Institute of Medical Science of the University of Tokyo, Chiba University, and Asahi Kogyosha Enter into Collaborative Research Agreement on Rice-based Oral Vaccine “MucoRice”
Dec 1, 2017

Astellas Acquires Mitobridge Under Existing Collaboration

-Accelerating the Discovery and Development of Novel Drugs that Target Mitochondrial Functions -

Tokyo and Cambridge, November 30, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Mitobridge, Inc.1 (President and CEO: Kazumi Shiosaki,...

Read more about Astellas Acquires Mitobridge Under Existing Collaboration
Dec 1, 2017

Astellas Announces Personnel Change

Read more about Astellas Announces Personnel Change
Nov 30, 2017

Astellas Submits a New Drug Application for Gonax® 12-Week Extended-Release Formulation for Treatment of Prostate Cancer in Japan

Tokyo, November 30, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that that it submitted an application for marketing approval in...

Read more about Astellas Submits a New Drug Application for Gonax® 12-Week Extended-Release Formulation for Treatment of Prostate Cancer in Japan
Nov 29, 2017

Astellas to Present New Data Exploring Gilteritinib in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients at the 2017 American Society of Hematology Annual Meeting (ASH)

– A breadth of abstracts highlighting the acute myeloid leukemia treatment landscape, healthcare resource use and cost of care to be presented during oral and poster sessions –

TOKYO – November 28, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced new data in acute myeloid leukemia (AML) research, including...

Read more about Astellas to Present New Data Exploring Gilteritinib in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients at the 2017 American Society of Hematology Annual Meeting (ASH)
Nov 28, 2017

MSD and Astellas conclude co-promotion agreement in Japan for type 2 diabetes combination drug

Drug combining selective DPP-4 inhibitor and selective SGLT2 inhibitor

Tokyo, November 28, 2017 -MSD K.K. (President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; “Astellas”) today announced that they have...

Read more about MSD and Astellas conclude co-promotion agreement in Japan for type 2 diabetes combination drug
Nov 8, 2017

Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer

Read more about Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
Oct 31, 2017

Astellas and FibroGen Announce Positive Topline Results from First Japan Phase 3 Trial for Roxadustat in Chronic Kidney Disease Patients with Anemia

Tokyo and San Francisco, October 31, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff,...

Read more about Astellas and FibroGen Announce Positive Topline Results from First Japan Phase 3 Trial for Roxadustat in Chronic Kidney Disease Patients with Anemia
Oct 30, 2017

Extension of Agreement Pertaining to Sale of Telmisartan (Micardis® family)

Tokyo, October 30, 2017 – Nippon Boehringer Ingelheim Co., Ltd. (President and Representative Director: Yoshiaki Aono, “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (President and...

Read more about Extension of Agreement Pertaining to Sale of Telmisartan (Micardis® family)

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts